September 2, 2025
Holmes Chapel, UK, 2 September 2025 — Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), has submitted net-zero and near-term company-wide emission reduction targets to the Science Based Targets initiative (SBTi), a corporate climate action organisation that enables companies and financial institutions worldwide to play their part in combatting the climate crisis.
Science-based targets offer companies a clear, actionable path to align emission reductions with the Paris Agreement goals, which seek to limit global warming to 1.5°C. Bespak has submitted its scope 1 and 2 emission reduction targets to the SBTi alongside its scope 3 near- and long-term targets, which are based on an economic intensity reduction, with a near-term target year of 2033 and long-term target year of 2050.
We have committed and submitted the following greenhouse gas emissions targets to SBTi for validation.
Bespak aims to reduce emissions in the most emission-intensive areas of its footprint, such as the use-phase of sold products, purchase of capital goods & services, and upstream transportation and distribution.
As a next step, SBTi will now assess and validate Bespak’s science-based targets against the SBTi’s criteria.
Chris Hirst, Bespak CEO, commented: ‘’Submitting our near-term and net-zero targets to the SBTi is a significant step toward aligning Bespak with a science-based, credible pathway to decarbonisation. We are integrating sustainability across our value chain and look forward to sharing our validated targets in due course.’’
Benedicta Bakpa, Head of ESG at Bespak, said: “As we work to decarbonise across scope 1, 2 and 3 greenhouse gas emissions, we are prioritising data-driven strategies and supplier engagement to ensure our targets are both credible and achievable. We look forward to working with the SBTi to finalise our targets and are excited to join this global movement to combat the climate crisis.”
For further information and interview opportunities with Bespak, please contact:
Sarah Guinane at Notch Communications
About Bespak:
Bespak is a specialist global contract development and manufacturing organisation (CDMO) solely focused on the inhaled and nasal drug delivery industry. It develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical market. Headquartered in Holmes Chapel, UK, Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation, product development and clinical supply, through to full-scale cGMP batch production.
With a long history in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), Bespak supplies a major proportion of the world’s pMDI dosing valves and actuators. Built on established expertise but ready for the future, Bespak is a long-term innovation partner committed to driving sustainability in the industry. The company has both established capacity and ongoing expansions to enable the manufacture of pMDIs with low Global Warming Potential (GWP) propellants, making it well positioned to lead the green pMDI transition.
More information: www.bespak.com
